These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2007-002371-13 A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with “triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Stud... not-yet-due
Not reported 2008-003930-19 Essai multicentrique randomisé de phase II comparant le Taxotère® en monothérapie à l’association Taxotère® plus curcumine en première ou deuxième ligne de traitement des cancers du sein inopérables, ... 2017-10-30 due-trials
Completed, but no date 2009-011423-31 Essai pilote de phase II évaluant l'association Taxotère® plus curcumine en première ligne de traitement des cancers de la prostate métastatiques hormono-résistants bad-data
Ongoing 2009-012853-39 Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. not-yet-due
Ongoing 2012-004103-12 ISOTOVE study not-yet-due
Ongoing 2012-005213-39 Phase II pilot study assessing efficacy of a Cisplatine – Métronomic not-yet-due
Ongoing 2013-001275-21 Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer not-yet-due
Completed, but no date 2013-002138-20 Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistan... bad-data